Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Li, Jiaming ^a   Wang, Zhaoyue ^a   Dai, Lan ^a   Cao, Lijuan ^a   Su, Jian ^a   Zhu, Mingqing ^a   Yu, Ziqiang ^a   Bai, Xia ^a   Ruan, Changgeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PREDNISONE; RAPAMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893808790     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/548085     Document Type: Article

References (35)

1. Ji L., Zhan Y., Hua F., The ratio of treg/th17 cells correlates with the disease activity of primary immune thrombocytopenia. PLoS One 2012 7 e50909 10.1371/journal.pone.0050909
2. Teke H. U., Gunduz E., Akay O. M., Gulbas Z., Abnormality of regulatory T-cells in remission and non-remission idiopathic thrombocytopaenic purpura patients. Platelets 2013 24 8 625 631 10.3109/09537104.2012.748188
3. + T cells in children with idiopathic thrombocytopenic purpura. Journal of Pediatric Hematology/Oncology 2011 33 2 81 85 2-s2.0-79952185498 10.1097/MPH.0b013e3181f46b82
4. Yu J., Heck S., Patel V., Levan J., Yu Y., Bussel J. B., Yazdanbakhsh K., Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008 112 4 1325 1328 2-s2.0-51649127854 10.1182/blood-2008-01-135335
5. Peterson R. A., Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicologic Pathology 2012 40 2 186 204 2-s2.0-84858768465 10.1177/0192623311430693
6. Semple J. W., Provan D., The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Current Opinion in Hematology 2012 19 5 357 362 10.1097/MOH.0b013e3283567541
7. Olsson B., Andersson P.-O., Jernås M., Jacobsson S., Carlsson B., Carlsson L. M. S., Wadenvik H., T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Medicine 2003 9 9 1123 1124 2-s2.0-0141684568 10.1038/nm921 (Pubitemid 37173694)
8. + regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. European Journal of Haematology 2007 79 4 310 316 2-s2.0-34548595302 10.1111/j.1600-0609. 2007.00917.x (Pubitemid 47390130)
9. Stasi R., Cooper N., Poeta G. D., Stipa E., Evangelista M. L., Abruzzese E., Amadori S., Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell depleting therapy with rituximab. Blood 2008 112 4 1147 1150 2-s2.0-51649091745 10.1182/blood-2007-12- 129262
10. Li Z., Mou W., Lu G., Cao J., He X., Pan X., Xu K., Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. International Journal of Hematology 2011 93 1 91 98 2-s2.0-78751580375 10.1007/s12185-010-0753-z
11. Bao W., Bussel J. B., Heck S., He W., Karpoff M., Boulad N., Yazdanbakhsh K., Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010 116 22 4639 4645 2-s2.0-78649486228 10.1182/blood-2010-04-281717
12. Food and Drug Administration, FDA approves rapamune to prevent organ rejection. http://www.fda.gov/bbs/topics/ANSWERS/ANS00974.html
13. Battaglia M., Stabilini A., Tresoldi E., Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods in Molecular Biology 2012 821 279 293 2-s2.0-84555187731 10.1007/978-1-61779-430-8-17
14. Delgoffe G. M., Powell J. D., Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes. Methods in Molecular Biology 2012 821 317 327 2-s2.0-84555189464 10.1007/978-1-61779-430-8-20
15. Delgoffe G. M., Kole T. P., Zheng Y., Zarek P. E., Matthews K. L., Xiao B., Worley P. F., Kozma S. C., Powell J. D., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009 30 6 832 844 2-s2.0-66949173728 10.1016/j.immuni.2009.04.014
16. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006 108 1 390 399 2-s2.0-33745633856 10.1182/blood-2006-01-0329 (Pubitemid 43990654)
17. + Tregs. Nephrology Dialysis Transplantation 2010 25 3 710 717 2-s2.0-77649217359 10.1093/ndt/gfp586
18. + regulatory T cells. Blood 2005 105 12 4743 4748 2-s2.0-20444373376 10.1182/blood-2004-10-3932 (Pubitemid 40807298)
19. +Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation. Cellular Immunology 2010 264 2 111 113 2-s2.0-77955093089 10.1016/j.cellimm.2010.05.014
20. + regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transplant Immunology 2012 26 1 1 10 2-s2.0-82955237325 10.1016/j.trim.2011.08.009
21. Coghill J. M., Carlson M. J., Moran T. P., Serody J. S., The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leukemia and Lymphoma 2008 49 10 1860 1869 2-s2.0-55049124957 10.1080/10428190802272684
22. Iwase H., Kobayashi T., Kodera Y., Miwa Y., Kuzuya T., Iwasaki K., Haneda M., Katayama A., Takeda A., Morozumi K., Watarai Y., Uchida K., Nakao A., Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation. Transplantation 2011 91 2 191 198 2-s2.0-78751648601 10.1097/TP.0b013e3181ffbab4
23. + regulatory T cells of both healthy subjects and type 1 diabetic patients. Journal of Immunology 2006 177 12 8338 8347 2-s2.0-33845379986 (Pubitemid 44893795)
24. Breakey V. R., Blanchette V. S., Childhood immune thrombocytopenia: a changing therapeutic landscape. Seminars in Thrombosis and Hemostasis 2011 37 7 745 755 2-s2.0-84255177131 10.1055/s-0031-1297165
25. Lai Z. W., Hanczko R., Bonilla E., N -acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 2012 64 9 2937 2946 10.1002/art.34502
26. Bruyn G. A., Tate G., Caeiro F., Maldonado-Cocco J., Westhovens R., Tannenbaum H., Bell M., Forre O., Bjorneboe O., Tak P. P., Abeywickrama K. H., Bernhardt P., Van Riel P. L. C., Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Annals of the Rheumatic Diseases 2008 67 8 1090 1095 2-s2.0-47949110435 10.1136/ard.2007.078808
27. + regulatory T cells in idiopathic thrombocytopenic purpura. European Journal of Haematology 2007 78 2 139 143 2-s2.0-33846059033 10.1111/j.1600-0609.2006.00780.x (Pubitemid 46058876)
28. + regulatory T Cells in the pathophysiology of immune thrombocytopenia. Seminars in Hematology 2013 50 supplement 1 S43 S49 10.1053/j.seminhematol.2013.03.018
29. Hilchey S. P., Bernstein S. H., Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD4+ and CD8+ T-cell proliferation within unseparated mononuclear cells from malignant and non-malignant human lymph node biopsies. Immunological Investigations 2007 36 5-6 629 648 2-s2.0-37649012017 10.1080/08820130701674463
30. Choudhary D. R., Naithani R., Mahapatra M., Kumar R., Mishra P., Saxena R., Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica 2008 93 10 e61 e62 2-s2.0-54349110881 10.3324/haematol.13481
31. Emilia G., Luppi M., Morselli M., Forghieri F., Potenza L., Torelli G., A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. Haematologica 2008 93 7 1113 1115 2-s2.0-46849091977 10.3324/haematol.12741 (Pubitemid 351957040)
32. Emilia G., Morselli M., Luppi M., Longo G., Marasca R., Gandini G., Ferrara L., D'Apollo N., Potenza L., Bertesi M., Torelli G., Long-term salvage therapy with cyclosporin a in refractory idipathic thrombocytopenic purpura. Blood 2002 99 4 1482 1485 2-s2.0-0037082457 10.1182/blood.V99.4.1482 (Pubitemid 34547109)
33. Arnold D. M., Nazi I., Santos A., Chan H., Heddle N. M., Warkentin T. E., Kelton J. G., Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood 2010 115 1 29 31 2-s2.0-74949115473 10.1182/blood-2009-06-222448
34. + regulatory T cells in inflamed synovia. Journal of Experimental Medicine 2005 201 11 1793 1803 2-s2.0-22344432319 10.1084/jem.20050085 (Pubitemid 41002898)
35. + regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis & Rheumatism 2007 56 3 732 742 2-s2.0-33947168299 10.1002/art.22414 (Pubitemid 46399420)